Data Sheet 7_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Table 9_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 1_The Emotional Recession: global declines in emotional intelligence and its impact on organizational retention, burnout, and workforce resilience.pdf by Joshua M. Freedman (22604039)

“…</p>Results<p>Global EQ scores declined by 5.79% (Cohen’s d = 0.22, 95% CI [0.17, 0.27]), with statistically significant decreases across all eight competencies (p < 0.001). …”

Data Sheet 8_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Table 5_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Table 2_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 5_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 11_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 2_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Table 8_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 1_FTO rs9939609 and rs17817449 polymorphisms contribute to metabolic syndrome risk by increasing triglyceride and glucose levels.docx by Yongyan Song (4415074)

“…</p>Results<p>The MetS group showed higher frequencies of rs9939609 A allele (14.01% vs. 6.09%, P < 0.001) and rs17817449 G allele (16.94% vs. 12.18%, P = 0.012) compared to controls. …”

Table 1_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 1_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Lomie district map. by Arnauld Efon-Ekangouo (15295634)

“…</p><p>Methodology/principal findings</p><p>A quantitative cross-sectional study was conducted in 10 schools of the Lomie Health District, East Region, Cameroon. …”

Table 1_Evaluating the Implementation of fan-beam CT-guided online adaptive re-planning in definitive cervical cancer radiotherapy.docx by Shuai Sun (775057)

“…All patients received external beam radiation therapy (EBRT) with a prescription dose of 50.4 Gy/28f, and daily oART with FBCT guidance was performed. …”

Table 4_The SlERF4-9-SlCDF1/3-SlAEC2/SlPIN5 module regulates tomato root morphogenesis.xlsx by ZhengFeng Fan (20950202)

“…The fresh weight, drought weight, number of primary lateral roots (LRs), average root diameter, and number of root tips were also decreased in the mutant. The findings suggest that SlERF4-9 plays a significant role in root growth and development. …”

Table 5_The SlERF4-9-SlCDF1/3-SlAEC2/SlPIN5 module regulates tomato root morphogenesis.xlsx by ZhengFeng Fan (20950202)

“…The fresh weight, drought weight, number of primary lateral roots (LRs), average root diameter, and number of root tips were also decreased in the mutant. The findings suggest that SlERF4-9 plays a significant role in root growth and development. …”

Table 3_The SlERF4-9-SlCDF1/3-SlAEC2/SlPIN5 module regulates tomato root morphogenesis.xlsx by ZhengFeng Fan (20950202)

“…The fresh weight, drought weight, number of primary lateral roots (LRs), average root diameter, and number of root tips were also decreased in the mutant. The findings suggest that SlERF4-9 plays a significant role in root growth and development. …”

Image 1_The SlERF4-9-SlCDF1/3-SlAEC2/SlPIN5 module regulates tomato root morphogenesis.jpeg by ZhengFeng Fan (20950202)

“…The fresh weight, drought weight, number of primary lateral roots (LRs), average root diameter, and number of root tips were also decreased in the mutant. The findings suggest that SlERF4-9 plays a significant role in root growth and development. …”

Data Sheet 1_Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.pdf by Paulo Rodrigues-Santos (3424613)

“…Therapy duration revealed 59.1% treated for less than 12 months (<12M) and 40.9% for 12 or more months (≥12M). A significant PFS improvement was observed in SD versus PD patients (p=0.0154), while therapy duration showed no effect (p=0.5433). …”